scholarly journals Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification

2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Philip D. Dunne ◽  
Matthew Alderdice ◽  
Paul G. O'Reilly ◽  
Aideen C. Roddy ◽  
Amy M. B. McCorry ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Cancer Patient ◽  
Cancer Cell ◽  
Colorectal Cancer Patient ◽  
Patient Classification ◽  
Intrinsic Gene ◽  
Gene Expression Signatures ◽  
Intratumoural Heterogeneity ◽  
Heterogeneity Bias

scholarly journals Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Jiao Wu ◽  
Sai-Ching Jim Yeung ◽  
Sicheng Liu ◽  
Aiham Qdaisat ◽  
Dewei Jiang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Weight Loss ◽  
Cancer Patients ◽  
Cancer Cell ◽  
Cancer Progression ◽  
Colorectal Cancer Patient ◽  
Nutrition Support ◽  
Immunodeficient Mice ◽  
The Impact

AbstractWeight loss and cachexia are common problems in colorectal cancer patients; thus, parenteral and enteral nutrition support play important roles in cancer care. However, the impact of nonessential amino acid components of nutritional intake on cancer progression has not been fully studied. In this study, we discovered that gastrointestinal cancer patients who received cysteine as part of the parenteral nutrition had shorter overall survival (P < 0.001) than those who did not. Cystine indeed robustly promotes colon cancer cell growth in vitro and in immunodeficient mice, predominately by inhibiting SESN2 transcription via the GCN2-ATF4 axis, resulting in mTORC1 activation. mTORC1 inhibitors Rapamycin and Everolimus block cystine-induced cancer cell proliferation. In addition, cystine confers resistance to oxaliplatin and irinotecan chemotherapy by quenching chemotherapy-induced reactive oxygen species via synthesizing glutathione. We demonstrated that dietary deprivation of cystine suppressed colon cancer xenograft growth without weight loss in mice and boosted the antitumor effect of oxaliplatin. These findings indicate that cyst(e)ine, as part of supplemental nutrition, plays an important role in colorectal cancer and manipulation of cyst(e)ine content in nutritional formulations may optimize colorectal cancer patient survival.

Abstract 1912: An explorative analysis ofERCC1/ERCC4copy number alterations in a chemonaive stage III colorectal cancer patient cohort.

2013 ◽  
Author(s):  
David H. Smith ◽  
Niels F. Jensen ◽  
Ib J. Christensen ◽  
Sven Müller ◽  
Hans J. Nielsen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patient ◽  
Colorectal Cancer Patient ◽  
Stage Iii ◽  
Patient Cohort

VEGFR1+ Metastasis–Associated Macrophages Contribute to Metastatic Angiogenesis and Influence Colorectal Cancer Patient Outcome

2019 ◽  
Vol 25 (18) ◽  
pp. 5674-5685 ◽  
Author(s):  
Aida Freire Valls ◽  
Karl Knipper ◽  
Evangelia Giannakouri ◽  
Víctor Sarachaga ◽  
Sascha Hinterkopf ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Patient Outcome ◽  
Cancer Patient ◽  
Colorectal Cancer Patient

Moving forward after cancer: successful implementation of a colorectal cancer patient–centered transitions program

2019 ◽  
Vol 14 (1) ◽  
pp. 4-8 ◽  
Author(s):  
Benjamin A. Goldenberg ◽  
Tara Carpenter-Kellett ◽  
Joel R. Gingerich ◽  
Zoann Nugent ◽  
Jeffrey J. Sisler
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patient ◽  
Colorectal Cancer Patient ◽  
Successful Implementation ◽  
Patient Centered ◽  
After Cancer
Sign in / Sign up

Export Citation Format

Share Document